271 related articles for article (PubMed ID: 33574892)
21. Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials.
Elmakaty I; Abdo R; Elsabagh A; Elsayed A; Malki MI
Cancer Cell Int; 2023 May; 23(1):90. PubMed ID: 37170090
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im SA; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Ann Oncol; 2020 May; 31(5):569-581. PubMed ID: 32278621
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
25. Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.
Bagegni NA; Davis AA; Clifton KK; Ademuyiwa FO
Breast Cancer (Dove Med Press); 2022; 14():113-123. PubMed ID: 35515356
[TBL] [Abstract][Full Text] [Related]
26. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Gianni L; Huang CS; Egle D; Bermejo B; Zamagni C; Thill M; Anton A; Zambelli S; Bianchini G; Russo S; Ciruelos EM; Greil R; Semiglazov V; Colleoni M; Kelly C; Mariani G; Del Mastro L; Maffeis I; Valagussa P; Viale G
Ann Oncol; 2022 May; 33(5):534-543. PubMed ID: 35182721
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Sternschuss M; Yerushalmi R; Saleh RR; Amir E; Goldvaser H
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3369-3379. PubMed ID: 33745080
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
29. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Saji S; Ohsumi S; Ito M; Hayashi N; Kobayashi K; Masuda N; Niikura N; Yamashita T; Kiyama K; Hasegawa A; Nakagawa S; Hattori M
Jpn J Clin Oncol; 2022 Oct; 52(10):1124-1133. PubMed ID: 35750038
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Zhang M; Song J; Yang H; Jin F; Zheng A
Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
Giugliano F; Valenza C; Tarantino P; Curigliano G
Expert Opin Investig Drugs; 2022 Aug; 31(8):855-874. PubMed ID: 35762248
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis.
Mittal N; Singh S; Mittal R; Kaushal J; Kaushal V
J Cancer Res Ther; 2022; 18(6):1754-1765. PubMed ID: 36412440
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
34. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Lehmann BD; Abramson VG; Dees EC; Shah PD; Ballinger TJ; Isaacs C; Santa-Maria CA; An H; Gonzalez-Ericsson PI; Sanders ME; Newsom KC; Abramson RG; Sheng Q; Hsu CY; Shyr Y; Wolff AC; Pietenpol JA
JAMA Oncol; 2024 Feb; 10(2):193-201. PubMed ID: 38095878
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data.
Deng H; Wang L; Wang N; Zhang K; Zhao Y; Qiu P; Qi X; Zhang D; Xu F; Liu J
BMC Cancer; 2023 Jan; 23(1):29. PubMed ID: 36611131
[TBL] [Abstract][Full Text] [Related]
36. Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer.
Hao X; Gao X; Yin S; Jiang Z
Transl Breast Cancer Res; 2023; 4():6. PubMed ID: 38751481
[TBL] [Abstract][Full Text] [Related]
37. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
Kagihara JA; Andress M; Diamond JR
Expert Rev Precis Med Drug Dev; 2020; 5(2):59-65. PubMed ID: 32190733
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy Approaches for Breast Cancer Patients in 2023.
Emens LA; Loi S
Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999
[TBL] [Abstract][Full Text] [Related]
39. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
[TBL] [Abstract][Full Text] [Related]
40. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
Rizzo A; Cusmai A; Acquafredda S; Giovannelli F; Rinaldi L; Misino A; Palmiotti G
Future Oncol; 2022 Jun; 18(18):2301-2309. PubMed ID: 35378995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
